Gastric cancer (GC) is the fifth most prevalent cancer worldwide and represents the third leading cause of cancer-related deaths globally.[110] HER-2 expression status has emerged as a crucial indicator for GC patients, guiding targeted therapy decisions, and accurate assessment of HER-2 gene status at diagnosis plays a pivotal role in clinical treatment planning.[111,112] Liu et al.[20] demonstrated the superior diagnostic performance of [18F]FDG PET/CT radiomics in distinguishing HER2+ expression from HER2− expression and predicting prognosis in patients with GC. This evidence concerns the gene ERBB2 and cancer.